OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company” or “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company.

佛罗里达州奥尔德斯马尔（商业新闻短讯）--Cryo-Cell International，Inc.（纽约证券交易所美国有限责任公司：CCEL）（“公司”或“Cryo-Cell”）是1992年世界上第一家分离和储存干细胞的私人脐带血库，今天宣布，其董事会已授权将其新成立的子公司Celle Corp.分拆给Cryo-Cell股东，并探索Cryo-Cell（分拆后）的所有战略替代方案，以最大化股东价值，包括但不限于股权和/或债务融资和/或公司可能的出售或合并。

There is no assurance that such a transaction will take place..

无法保证此类交易会发生。。

Celle Corp. was created to hold certain assets of Cryo-Cell not directly associated with the recurring revenue stream from privately banked, umbilical cord blood specimens. The Patent and Technology License Agreement with Duke University has been transferred to Celle Corp. and other assets and liabilities are expected to be transferred in the near future.

Celle Corp.成立的目的是持有Cryo Cell的某些资产，这些资产与私人储存的脐带血样本的经常性收入流没有直接关系。与杜克大学签订的专利和技术许可协议已转让给Celle Corp.，其他资产和负债预计将在不久的将来转让。

The spin-off is currently anticipated to be in the form of a stock dividend to the Cryo-Cell shareholders and to occur in Cryo-Cell’s 2nd or 3rd fiscal quarters. Further details, once finalized, will be shared in public filings with the Securities and Exchange Commission..

目前预计分拆将以向Cryo Cell股东派发股票股息的形式进行，并将在Cryo Cell的第二或第三个财政季度进行。一旦最终确定，更多细节将在证券交易委员会的公开文件中共享。。

About Cryo-Cell International, Inc.

关于Cryo Cell International，Inc。

Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. ‎More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with ‎their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell ‎International has a public banking program in partnership with Duke University.

Cryo Cell International，Inc.成立于1989年，是世界上第一家私人脐带血库。‎来自87个国家的50多万名父母委托Cryo Cell International‎他们孩子的脐带血和脐带组织干细胞。除了它的私人银行Cryo Cell‎国际银行与杜克大学合作开设了一个公共银行项目。

Cryo-Cell’s ‎public bank has provided cord blood for more than 600 transplantations and operates cord ‎blood donation sites across the U.S in prominent hospitals such as Cedars–Sinai Hospital in ‎Los Angeles and Baptist Hospital in Miami. Cryo-Cell’s facility is FDA registered, cGMP-/cGTP-‎compliant and licensed in all states requiring licensure.

冷冻细胞‎公共银行已为600多例移植提供脐带血，并经营脐带业务‎美国各地著名医院的献血地点，如塞达斯-西奈医院‎洛杉矶和迈阿密浸礼会医院。Cryo Cell的设施是FDA注册的cGMP-/cGTP-‎在所有需要许可的州都符合要求并获得许可。

Besides being AABB accredited as a ‎cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to ‎receive FACT accreditation for adhering to the most stringent cord blood quality standards ‎set by any internationally recognized, independent accrediting organization.

除了被AABB认证为‎脐带血设施Cryo Cell也是美国第一家（仅供私人使用）脐带血库‎因遵守最严格的脐带血质量标准而获得事实认证‎由任何国际公认的独立认证组织设定。

Cryo-Cell has ‎the exclusive rights ‎to PrepaCyte-CB, the industry’s most advanced cord blood processing ‎technology.‎.

冷冻细胞具有‎专有权‎预酰化CB，业界最先进的脐带血加工‎技术。‎.

Cryo-Cell’s mission is to provide the premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available.

Cryo Cell的使命是提供一流的脐带血和脐带组织冷冻保存服务，开发，制造和管理细胞疗法，以显着改善全球患者的生活，并提供最高质量和最具成本效益的生物存储解决方案。

In February 2021, Cryo-Cell entered into a license agreement with Duke University ‎that the Company believes has allowed Cryo-Cell to begin its transformation into an autonomous, ‎‎vertically ‎integrated cellular therapy ‎company. ‎In March 2022, Cryo-Cell launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions.

2021年2月，Cryo Cell与杜克大学签订了许可协议‎该公司认为这使Cryo Cell开始转变为一个自主的，‎‎垂直‎综合细胞疗法‎公司。‎2022年3月，Cryo Cell推出了ExtraVault，为生物制药公司和医疗机构提供生物储存和分销方面的专业知识。

For more information, please visit (www.extravault.com)..

有关更多信息，请访问（www.extravault.com）。。

Forward-Looking Statements

前瞻性声明

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terminology such as “will,” “may,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or the negative of these terms or other comparable terminology.

本新闻稿包括经修订的《1933年证券法》（“证券法”）第27A节和经修订的《1934年证券交易法》（“交易法”）第21E节所指的“前瞻性声明”。在某些情况下，您可以通过术语来识别前瞻性陈述，例如“将”、“可能”、“应该”、“可能”、“会”、“预期”、“计划”、“预期”、“相信”、“估计”、“预测”、“预测”、“潜在”或“继续”，或这些术语或其他类似术语的否定词。

Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements..

一般来说，“预期”、“相信”、“继续”、“预期”、“打算”、“估计”、“项目”、“计划”和类似的表达都可以识别前瞻性陈述。特别是，关于我们的期望、信念、计划、目标、假设或未来事件或表现的陈述包含前瞻性陈述。。

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance.

我们将这些前瞻性陈述建立在我们目前的预期、假设、估计和预测的基础上。这些前瞻性陈述涉及风险和不确定性，仅反映了我们对未来事件和未来表现的当前观点、期望和假设。

If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, risks related to: the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the Company’s global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company’s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to pr.

如果出现风险或不确定性或假设不正确，实际结果或事件可能与此类前瞻性声明中明示或暗示的结果或事件存在重大差异。可能导致实际结果与我们所做的前瞻性陈述中明示或暗示的结果不同的风险包括以下相关风险：新型冠状病毒肺炎对我们的销售、运营和供应链的影响，公司全球扩张计划和产品多样化的成功，包括增加ExtraVault服务，公司在合作研究伙伴关系中产生的未来疗法中的实际未来所有权股份，与其知识产权组合相关的成功，公司未来在干细胞创新中的竞争地位，其核心业务的未来成功以及公共脐带血银行对公司业务的竞争影响，公司扩大其核心业务部门以包括生物制药的计划的成功制药制造和运营诊所，其生物制药制造和运营诊所的盈利能力的不确定性，公司将研发计划和合作相关的未来成本降至最低的能力，此类计划和合作的成功，公司脐带血和脐带组织许可协议的成功和可执行性，以及相关知识产权及其公关能力。

This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.

然而，这份风险和不确定性清单只是对一些最重要因素的总结，并不打算详尽无遗。鉴于这些风险和不确定性，请注意不要过度依赖此类前瞻性声明。这些风险和不确定性可能导致我们的实际未来结果与我们的前瞻性声明中所表达的结果存在重大差异。

These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

这些前瞻性声明仅在本协议日期作出。除非适用法律另有要求，否则我们不承担并明确否认更新任何此类声明或公开宣布任何此类声明修订结果以反映未来事件或发展的任何义务。

All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements..

所有后续的书面和口头前瞻性声明均归责于本公司或代表本公司行事的人士，这些警示性声明明确限定了其全部内容。。